Advertisement

Early eradication has a lower risk of peptic ulcer bleeding in Helicobacter pylori-infected chronic kidney disease patients

  • Ching-Hui Hsu
    Affiliations
    Division of Allergy, Immunology, Rheumatology, Taipei City Hospital Yang-Ming Branch, Taiwan

    Department of Internal Medicine, Taipei City Hospital Yang-Ming Branch, Taiwan
    Search for articles by this author
  • Hsiao-Yun Hu
    Affiliations
    Institute of Public Health and Department of Public Health, National Yang-Ming University, Taiwan

    Department of Education and Research, Taipei City Hospital, Taiwan
    Search for articles by this author
  • Nicole Huang
    Affiliations
    Institute of Hospital and Health Care Administration, National Yang-Ming University, Taiwan
    Search for articles by this author
  • Shen-Shong Chang
    Correspondence
    Corresponding author at: Division of Gastroenterology, Department of Internal Medicine, Taipei City Hospital Yang-Ming Branch, No 105, Yusheng Street, Shihlin District, Taipei 111 11217, Taiwan. Tel.: +886 2 28353456 6960; fax: +886 2 28389551.
    Affiliations
    Division of Gastroenterology, Taipei City Hospital Yang-Ming Branch, Taiwan

    Department of Internal Medicine, Taipei City Hospital Yang-Ming Branch, Taiwan

    School of Medicine, National Yang-Ming University, Taiwan

    Institute of Public Health and Department of Public Health, National Yang-Ming University, Taiwan
    Search for articles by this author

      Highlights

      • Early H. pylori eradication has a lower risk of PUB in CKD patients.
      • H. pylori eradication at Charlson's score more than 3 is a risk factor of PUB.
      • The incidence of PUB was higher in the ESRD cohort than in the pre-ESRD cohort.

      Abstract

      Background

      End stage renal disease (ESRD) contributes to a higher mortality rate in peptic ulcer bleeding (PUB) patients. A crucial question is whether early Helicobacter pylori (H. pylori) eradication therapy is necessary for H. pylori-infected chronic kidney disease (CKD) patients. To explore whether H. pylori eradication therapy has a lower risk of PUB at the pre-ESRD stage than at the ESRD stage.

      Methods and patients

      Patients meeting 2 criteria were defined as newly diagnosed ESRD cases: (1) patients diagnosed with ESRD and receiving regular dialysis between 2000 and 2009; and (2) patients with no history of dialysis between 1997 and 1999. We divided the study participants into pre-ESRD and ESRD groups on the basis of the time between H. pylori eradication and dialysis. The date of the first PUB diagnosis was defined as the primary endpoint. Stratified Cox proportional hazard regression analysis was used to estimate the effect of H. pylori eradication at the pre-ESRD and ESRD stage on the occurrence of PUB.

      Results

      We included 476 patients in the pre-ESRD cohort and 476 patients in the matched ESRD cohort. After adjustment for age, sex, the presence of comorbidities, and medication use, the hazard ratio of PUB was 0.66 times less in the pre-ESRD cohort than in the ESRD cohort. Factors such as Charlson's score more than 3, and nonsteroidal anti-inflammatory drugs were associated with an increased risk of PUB.

      Conclusion

      Our result supports that early H. pylori eradication has a lower risk of PUB in H. pylori-infected CKD patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Crooks C.J.
        • West J.
        • Card T.R.
        Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding.
        Gastroenterology. 2013; 144: 1384-1393
        • Rotondano G.
        Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding.
        Gastroenterol Clin North Am. 2014; 43: 643-663
        • Parasa S.
        • Navaneethan U.
        • Sridhar A.R.
        • Venkatesh P.G.
        • Olden K.
        End-stage renal disease is associated with worse outcomes in hospitalized patients with peptic ulcer bleeding.
        Gastrointest Endosc. 2013; 77: 609-616
        • Liang C.C.
        • Muo C.H.
        • Wang I.K.
        • Chang C.T.
        • Chou C.Y.
        • Liu J.H.
        • et al.
        Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications.
        PLoS One. 2014; 9e87952
        • Luo J.C.
        • Leu H.B.
        • Huang K.W.
        • Huang C.C.
        • Hou M.C.
        • Lin H.C.
        • et al.
        Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis.
        CMAJ. 2011; 183: E1345-E1351
        • Wu C.Y.
        • Wu M.S.
        • Kuo K.N.
        • Wang C.B.
        • Chen Y.J.
        • Lin J.T.
        Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study.
        Gut. 2011; 60: 1038-1042
        • McColl K.E.
        Clinical practice. Helicobacter pylori infection.
        N Engl J Med. 2010; 362: 1597-1604
        • Hopkins R.J.
        • Girardi L.S.
        • Turney E.A.
        Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review.
        Gastroenterology. 1996; 110: 1244-1252
        • Kang J.Y.
        • Ho K.Y.
        • Yeoh K.G.
        • Guan R.
        • Wee A.
        • Lee E.
        • et al.
        Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection.
        Gastroenterol Hepatol. 1999; 14: 771-778
        • Tseng G.Y.
        • Lin H.J.
        • Fang C.T.
        • Yang H.B.
        • Tseng G.C.
        • Wang P.C.
        • et al.
        Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study.
        Aliment Pharmacol Ther. 2007; 26: 925-933
        • Gur G.
        • Boyacioglu S.
        • Gul C.
        • Turan M.
        • Gursoy M.
        • Baysal C.
        • et al.
        Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients.
        Nephrol Dial Transplant. 1999; 14: 2688-2691
        • Tseng G.Y.
        • Lin H.J.
        Aspirin prescription and outcomes in hemodialysis patients.
        Am J Kidney Dis. 2008; 51: 1070-1071
        • Sugimoto M.
        • Sakai K.
        • Kita M.
        • Imanishi J.
        • Yamaoka Y.
        Prevalence of Helicobacter pylori infection in long-term hemodialysis patients.
        Kidney Int. 2009; 75: 96-103
        • Lin S.C.
        • Wu K.L.
        • Chiu K.W.
        • Lee C.T.
        • Chiu Y.C.
        • Chou Y.P.
        • et al.
        Risk factors influencing the outcome of peptic ulcer bleeding in end stage renal disease after initial endoscopic haemostasis.
        Int J Clin Pract. 2012; 66: 774-781
        • Toke A.B.
        GI bleeding risk in patients undergoing dialysis.
        Gastrointest Endosc. 2010; 71: 50-52
        • Rosenbaum P.R.
        • Rubin D.B.
        The central role of the propensity score in observational studies for causal effects.
        Biometrika. 1983; 79: 516-524
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies.
        J Chronic Dis. 1987; 40: 373-383
        • Hsu Y.C.
        • Lin J.T.
        • Chen T.T.
        • Wu M.S.
        • Wu C.Y.
        Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study.
        Hepatology. 2012; 56: 698-705
        • Pereira B.J.
        Optimization of pre-ESRD care: the key to improved dialysis outcomes.
        Kidney Int. 2000; 57: 351-365
        • Malfertheiner P.
        • Megraud F.
        • O'Morain C.
        • Bazzoli F.
        • El-Omar E.
        • Graham D.
        • et al.
        Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.
        Gut. 2007; 56: 772-781
        • Khedmat H.
        • Ahmadzad-Asl M.
        • Amini M.
        • Lessan-Pezeshki M.
        • Einollahi B.
        • Pourfarziani V.
        • et al.
        Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients.
        Transplant Proc. 2007; 39: 1003-1007
        • Sugimoto M.
        • Yamaoka Y.
        Review of Helicobacter pylori infection and chronic renal failure.
        Ther Apher Dial. 2011; 15: 1-9
        • Leontiadis G.I.
        • Molloy-Bland M.
        • Moayyedi P.
        • Howden C.W.
        Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis.
        Am J Gastroenterol. 2013; 108: 331-345
        • Sheu B.S.
        • Wu C.Y.
        • Wu M.S.
        • Chiu C.T.
        • Lin C.C.
        • Hsu P.I.
        • et al.
        Consensus on control of risky nonvariceal upper gastrointestinal bleeding in Taiwan with National Health Insurance.
        Biomed Res Int. 2014; 563707: 2014
        • Laursen S.B.
        • Hansen J.M.
        • Hallas J.
        • Schaffalitzky de Muckadell O.B.
        the excess long-term mortality in peptic ulcer bleeding is explained by nonspecific comorbidity.
        Scand J Gastroenterol. 2015; 50: 145-152
        • Chan F.K.
        • Sung J.J.
        Role of acid suppressants in prophylaxis of NSAID damage.
        Best Pract Res Clin Gastroenterol. 2001; 15: 433-445
        • Kauffman G.
        Aspirin-induced gastric mucosal injury: lessons learned from animal models.
        Gastroenterology. 1989; 96: 606-614
        • Sostres C.
        • Carrera-Lasfuentes P.
        • Benito R.
        • Roncales P.
        • Arruebo M.
        • Arroyo M.T.
        • et al.
        Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users.
        Am J Gastroenterol. 2015; 110: 684-689
        • Ljubicic N.
        • Puljiz Z.
        • Budimir I.
        • Biscanin A.
        • Bratanic A.
        • Pavic T.
        • et al.
        The influence of etiologic factors on clinical outcome in patients with peptic ulcer bleeding.
        Dig Dis Sci. 2012; 57: 3195-3204
        • Van Dam J.
        • Brugge W.R.
        Endoscopy of the upper gastrointestinal tract.
        N Engl J Med. 1999; 341: 1738-1748
        • Morgan D.R.
        • Torres J.
        • Sexton R.
        • Herrero R.
        • Salazar-Martinez E.
        • Greenberg E.R.
        • et al.
        Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
        JAMA. 2013; 309: 578-586
        • Aydemir S.
        • Boyacioglu S.
        • Gur G.
        • Demirbilek M.
        • Can F.K.
        • Korkmaz M.
        • et al.
        Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin.
        World J Gastroenterol. 2005; 11: 842-845